Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice

Cancer Research

Volumn 62, Issue 1, 2002, Pages 24-27

  Hayashi, Takuma ^a   Faustman, Denise L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; POLYPEPTIDE; PROTEASOME;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL CYCLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME SUBUNIT; FEMALE; KNOCKOUT MOUSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; UTERUS DISEASE; UTERUS TUMOR;

ANIMALS; CYSTEINE ENDOPEPTIDASES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOLOGIC SURVEILLANCE; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; PROTEIN BIOSYNTHESIS; PROTEINS; UTERINE NEOPLASMS;

EID: 0036141520     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. A ubiquitin ligase complex essential for the NF-κB, Wnt/Wingless, and Hedgehog signaling pathways
2. Interferon-γ inducible exchanges of 20S proteasome active site subunits: Why?
3. A role of interferon-γ (IFN-γ) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-γdeficient mice
4. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
5. γ-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes
6. Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin
7. Loss of interferon-γ inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line
8. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells
9. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histo-compatibility complex in tumor cell lines
10. Altered peptidase and viral-specific T cell response in LMP2 mutant mice
11. NOD mice are defective in proteasome production and activation of NF-κB
12. Essential role of human leukocyte antigen-encoded proteasome subunits in NF-κB activation and prevention of tumor necrosis factor-α-induced apoptosis
13. Manipulation of immune response
14. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming
15. Tumor antigens recognized by T lymphocytes
16. Human tumor antigens for cancer vaccine development
17. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
18. T cells and tumours
19. Proteasome inhibition: A novel mechanism to combat asthma
20. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity
21. Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia
22. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer